Mineralys Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
$MLYS
Biotechnology: Pharmaceutical Preparations
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 21, 2026
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||
(Address of principal executive offices) (Zip Code) | ||||||||
( | ||||||||
(Registrant’s telephone number, including area code) | ||||||||
Not Applicable | ||||||||
(Former name or former address, if changed since last report) | ||||||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
On May 21, 2026, Mineralys Therapeutics, Inc. (the Company) held its 2026 annual meeting of stockholders (the Annual Meeting). The following matters (the Proposals) were voted upon by the stockholders with the final voting results as shown:
Proposal 1 — To elect three directors to serve as Class III directors for a three-year term to expire at the 2029 annual meeting of stockholders.
Name | For | Withhold | Broker Non-Votes | |||||||||||||||||
Srinivas Akkaraju, M.D., Ph.D. | 40,667,555 | 26,447,538 | 5,569,960 | |||||||||||||||||
Brian Taylor Slingsby, M.D., Ph.D., M.P.H. | 42,487,140 | 24,627,953 | 5,569,960 | |||||||||||||||||
Daphne Karydas | 66,626,766 | 488,327 | 5,569,960 | |||||||||||||||||
Proposal 2 — To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
For | Against | Abstain | Broker Non-Votes | |||||||||||||||||
72,648,272 | 9,516 | 27,265 | 0 | |||||||||||||||||
Both Proposals were approved, each receiving the affirmative requisite vote of the holders of shares of the Company’s common stock.
Each Proposal is described in detail in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 8, 2026.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: May 22, 2026 | MINERALYS THERAPEUTICS, INC. | |||||||
| By: | /s/ Adam Levy | |||||||
| Name: | Adam Levy | |||||||
| Title: | Chief Financial Officer and Secretary | |||||||